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Abstract
A fundamental tenet of heart failure (HF) pathophysiology hinges on a
propensity for fluid retention leading to blood volume (BV) expansion and
hemodilution. Whether this can be applied to heart failure patients with pre-
served ejection fraction (HFpEF) remains uncertain. The present study sought
to determine BV status and key hormones regulating fluid homeostasis and
erythropoiesis in HFpEF patients. BV and hemoglobin mass (Hbmass) were
determined with high-precision, automated carbon monoxide (CO) rebreath-
ing in 20 stable HFpEF patients (71.5  7.3 years, left ventricular ejection
fraction = 55.7  4.0%) and 15 healthy age- and sex-matched control individ-
uals. Additional measurements comprised key circulating BV-regulating hor-
mones such as pro-atrial natriuretic peptide (proANP), copeptin, aldosterone
and erythropoietin (EPO), as well as central hemodynamics and arterial stiff-
ness via carotid–femoral pulse wave velocity (PWV). Carotid–femoral PWV
was increased (+20%) in HFpEF patients versus control individuals. With
respect to hematological variables, plasma volume (PV) did not differ between
groups, whereas BV was decreased (14%) in HFpEF patients. In consonance
with the hypovolemic status, Hbmass was reduced (27%) in HFpEF patients,
despite they presented more than a twofold elevation of circulating EPO
(+119%). Plasma concentrations of BV-regulating hormones, including
proANP (+106%), copeptin (+99%), and aldosterone (+62%), were substan-
tially augmented in HFpEF patients. HFpEF patients may present with hypov-
olemia and markedly reduced Hbmass, underpinned by a generalized
overactivation of endocrine systems regulating fluid homeostasis and erythro-
poiesis. These findings provide a novel perspective on the pathophysiological
basis of the HFpEF condition.
Introduction
A fundamental principle of cardiovascular physiology
refers to the strict dependence of cardiac reserve upon
blood volume (BV), which facilitates venous return, ven-
tricular filling, and stroke volume via the Frank–Starling
mechanism (Guyton and Hall 2011; Bonne et al. 2014;
Montero et al. 2015). Indeed, BV is a tightly regulated
fluid varying as little as 4% over several months in
healthy individuals, plausibly owing to its central role in
maintaining whole body homeostasis (Montero and
Flammer 2017; Montero and Lundby 2017). In the
presence of a failing heart, acute fluid retention leading
to BV expansion is considered a disproportionate com-
pensatory response in the attempt to retrieve cardiac
reserve, eventually resulting in clinical congestion (Guy-
ton and Hall 2011). BV may exceed 120 mLkg1 in
untreated heart failure (HF) patients, a ~1.5-fold
increase compared with healthy individuals (Kaplan
et al. 1954). In contrast, reduced BVs have been
reported in stable HF patients treated with standard
pharmacotherapy, including diuretics, after congestion
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has been alleviated (Anand et al. 1989; Feigenbaum
et al. 2000; Bonfils et al. 2010).
Finely tailored medication may be required to sustain
euvolemia in HF patients, a challenging task for clinicians
since the quantitative measurement of BV is not yet
established in the clinical arena (Miller 2016; Ellison and
Felker 2017). This uncertainty may particularly affect the
hemodynamic stability of HF patients with preserved ejec-
tion fraction (HFpEF), a condition characterized by car-
diovascular stiffening, limited pressure gradient propelling
venous return to the heart, and severe exercise intolerance
as a chronic symptom (Schwartzenberg et al. 2012; Mon-
tero and Flammer 2017). In these patients, small random-
ized controlled trials of diuretic withdrawal have shown
improvements in ventricular filling and orthostatic toler-
ance as well as reduced overactivation of the renin–an-
giotensin–aldosterone system (RAAS), a major endocrine
system contributing to the regulation of BV (van Kraaij
et al. 2000; 2003). The effects of diuretic withdrawal in
HFpEF patients are thus consistent with prior hypov-
olemia. Yet, relatively little is currently known regarding
the BV status of stable HF populations. To date, a single
report has indirectly estimated a high prevalence of hypo-
volemia in HFpEF patients relative to normal BV values
derived from anthropometric tables (Abramov et al.
2008). Importantly, a substantial deficit in total hemoglo-
bin mass (Hbmass), limiting maximal aerobic capacity
(Montero and Flammer 2017; Lundby et al. 2017), may
be concealed in hypovolemic HFpEF patients presenting
with unaltered or slightly reduced blood hemoglobin
(Hb) concentration (Abramov et al. 2008). The combina-
tion of hypovolemia and reduced Hbmass could be an
overlooked dominant substrate in the pathophysiology of
HFpEF. An investigation aimed to characterize BV status
and its endocrine regulation, including hormones govern-
ing intravascular volumes and Hbmass, is warranted in
HFpEF patients, but to our knowledge, this has not yet
been performed.
The main purpose of the present study was to deter-
mine BV, Hbmass, and key hormones regulating fluid
homeostasis and erythropoiesis in stable HFpEF patients
and healthy age- and sex-matched control individuals.
We tested the hypothesis that patients with HFpEF will
demonstrate hypovolemia and reduced Hbmass in parallel
to altered endocrine regulation of BV and erythropoiesis.
Methods
Ethical approval
The study was approved by Ethical Commission of Zurich
(BASEC-Nr. 2016-02167) and conducted in accordance
with the Declaration of Helsinki. Prior to the start of the
experiments, informed oral and written consents were
obtained from all participants.
Study population
Twenty stable HFpEF patients (left ventricular ejection
fraction (LVEF) = 55.7  4.7%, 25% females) were
recruited from the HF outpatient clinic of the University
Hospital of Zurich. Inclusion criteria comprised: signs
and symptoms of HF (Ponikowski et al. 2016),
LVEF > 50%, elevated levels of N-terminal pro-b-type
natriuretic peptide (NT-proBNP > 125 pgmL1), rele-
vant structural/functional cardiac alterations, and no his-
tory of iron deficiency (ID) anemia. Healthy age- and
sex-matched individuals were recruited from the commu-
nity and excluded if they had any chronic medical illness,
were taking daily prescription medications, had current
medical symptoms, or were performing aerobic exercise
on a regular basis given its potential effect on BVs and
Hbmass (Montero and Flammer 2017, #34).
Experimental design
All measurements were accomplished within a period
spanning from 8:30 AM to 11:00 AM, after fasting over-
night in a quiet room with controlled temperature
between 22°C and 24°C. Upon arrival at the laboratory,
individuals completed demographic and clinical question-
naires and rested in the supine position for 10 min in
order to stabilize cardiovascular and hematological vari-
ables. Subsequently, hemodynamics, arterial stiffness, and
BV measurements were sequentially performed. Blood
and salivary samples were sent for immediate analysis to
the Institute of Clinical Chemistry (University Hospital
Zurich). Duplicates of blood samples were centrifuged
and stored at 80°C for further examination.
Experimental measures
Blood volumes and hemoglobin mass
The method to determine BVs and Hbmass comprised the
classic carbon monoxide (CO) rebreathing technique inte-
grated in a fully automated system with a very low typical
error of measurement (OpCO, Detalo, Denmark) (Dan-
danell et al. 2016; Montero et al. 2017). In brief, following
supine rest, 2 mL of blood was sampled from an antecu-
bital vein via a 20-G venflon (BD, USA) and analyzed
immediately in duplicate for percent carboxyhemoglobin
(%HbCO), Hb concentration, O2 saturation (sO2), and
hematocrit (Hct) with an hemoximeter (ABL800,
Radiometer, Denmark). Subsequently, individuals breathed
100% O2 for 4 min to flush the nitrogen from the airways.
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After closing the O2 input, a bolus of 1.5 mL kg
1 of
99.997% chemically pure CO (CO N47, Air Liquide,
France) was administrated into the breathing circuit. Indi-
viduals rebreathed this gas mixture for 10 min. Then, an
additional 2-mL blood sample was obtained and analyzed
in duplicate as aforementioned. The change in %HbCO is
used to calculate Hbmass, taking into account the amount of
CO that remains in the rebreathing circuit at the end of the
procedure. Total red blood cell volume (RBCV), plasma
volume (PV), and BV were determined from Hbmass, Hb,
and Hct (Dandanell et al. 2016; Montero et al. 2017).
Hematology
Blood samples (5 mL) from the antecubital vein were col-
lected anaerobically in heparinized glass syringes. Serum
creatinine was assessed via the kinetic Jaffe reaction (Hita-
chi P-Modular system, Roche Diagnostics, Switzerland).
Estimated glomerular filtration rate (eGFR) was calculated
using the CKD-EPI Creatinine Equation (2009) according
to the guidelines from the National Kidney Foundation
(Inker et al. 2014). Hormones measured in plasma
included pro-atrial natriuretic peptide (proANP), NT-
proBNP, copeptin (a surrogate of vasopressin) (Morgen-
thaler 2010), erythropoietin (EPO), and aldosterone. Pro-
atrial natriuretic peptide (proANP) was assessed with a
mid-regional assay on a Kryptor Plus platform (Thermo
Fisher, Germany) (Hunter et al. 2011), while NT-proBNP
was determined by immunoassay (Elecsys NT-proBNP,
Roche Diagnostics, Switzerland). Copeptin was assessed
using an automated immunofluorescent assay (Thermo
Fisher, Germany) (Morgenthaler et al. 2008; Balanescu
et al. 2011; Roussel et al. 2014). The Human EPO Quan-
tikine IVD ELISA Kit (R&D Systems Inc., USA) was used
to measure EPO. The observed/predicted (O/P) EPO ratio
was calculated according to the regression equation Log
(EPO) = 4.746  (0.275 9 Hb) (Beguin et al. 1993; Opa-
sich et al. 2005; Meer et al. 2008). Aldosterone and sali-
vary cortisol were quantified by means of a competitive
enzyme immunoassay (R&D Systems Inc., USA). In addi-
tion, in order to control for potential confounding acute
alterations in hemoconcentration, albumin levels were
assessed with ALB reagent in conjunction with UniCel
DxC 600/800 and Synchron Systems Multi Calibrator
(Beckman Coulter, USA).
Hemodynamics
The internal jugular vein (IJV) aspect ratio, a surrogate of
central venous pressure (CVP), was determined at the
level of the cricoid cartilage using the method described
by Keller et al. (2009) In brief, the left IJV was assessed
by means of a 7 MHz linear array probe attached to a
high-resolution ultrasound machine (SonixTouch, BK
Ultrasound, USA). After obtaining an optimized IJV
image, a 20-sec B-mode cine loop was obtained and
reviewed frame-by-frame to identify the largest cross-sec-
tional area (during expiration), and vessel dimensions
were recorded. The IJV height was divided by its width to
obtain the aspect ratio. In addition, pulse wave analysis
(PWA) was performed on radial artery pressure wave-
forms (SphygmoCor, AtCor Medical, Australia).
Arterial stiffness
Carotid–femoral pulse wave velocity (PWV) was assessed
with arterial tonometry (SphygmoCor, AtCor Medical,
Australia) according to established guidelines (Van Bor-
tel et al. 2012). Pressure waveforms were acquired at the
left common carotid and femoral arteries. To determine
carotid–femoral PWV, the difference in the time of pulse
arrival between common carotid and femoral arteries
from the R-wave of the electrocardiogram was calculated
using the intersecting tangent algorithm. Moreover, caro-
tid artery distensibility, a relatively less established assess-
ment of arterial stiffness, was assessed by means of high-
resolution ultrasound (SonixTouch, BK Ultrasound,
USA) (Van Bortel et al. 2002). The distensibility coeffi-
cient (DC) was calculated according to the following
formula:
DC ¼ ð2DD Dþ DD2Þ=ðPP  D2Þ
where D is the arterial diameter, ΔD is the distension,
and PP is the brachial pulse pressure. DC represents the
reciprocal value of arterial stiffness (AS).
Statistical analysis
Statistical analysis was performed using SPSS 22.0 (SPSS,
Chicago, IL). Data were tested for normal distribution
with the Kolmogorov–Smirnov test and for homogeneity
of variances with Levene’s test.
Fisher’s exact test, independent t-test, and Mann–Whit-
ney U-test were used to compare dichotomous, paramet-
ric, and nonparametric data, respectively, between HFpEF
patients and control individuals. Data are reported as
mean  SD unless otherwise stated. A two-tailed P-value
less than 0.05 was considered significant.
Results
Population characteristics
Baseline characteristics of HFpEF patients and control
individuals are reported in Table 1. HFpEF patients
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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presented with increased body mass index (P = 0.003)
and NT-proBNP (P < 0.001) while eGFR was mildly
reduced (P = 0.002) compared with control individuals.
Venous Hb concentration (P = 0.002) and Hct
(39.7  5.2 vs. 44.0  1.8%, P = 0.002) were also
reduced in HFpEF patients. No difference was detected
for venous sO2 (82.5  11.9 vs. 80.3  8.9%, P = 0.547)
between groups. The most prevalent comorbidities in
HFpEF patients were hypertension (80%), coronary artery
disease (55%), and diabetes mellitus (25%). With respect
to the medication, beta-blockers (70%), loop diuretics
(60%), and angiotensin-converting enzyme inhibitors/an-
giotensin II-receptor blockers (60%) were common and
similarly prevalent in HFpEF patients. Control individuals
were healthy and did not take medications.
Central hemodynamics and arterial stiffness
Table 2 presents hemodynamics and distensibility param-
eters of elastic arteries. HFpEF patients exhibited
augmented IJV aspect ratio, an estimate of CVP, com-
pared with control individuals (P = 0.034). Aortic
Aix@75 was similar between HFpEF patients and control
individuals. Likewise, carotid distensibility did not differ
between groups. In contrast, carotid–femoral PWV was
increased in HFpEF patients (P = 0.047).
Blood volumes and hemoglobin mass
(Hbmass)
Blood volumes in HFpEF patients and control individuals
are displayed in Figure 1. Both groups had comparable PV
(45.0  7.0 vs. 47.5  7.7 mLkg1, P = 0.324), whereas
RBCV (29.5  4.7 vs. 37.3  5.4 mLkg1, P < 0.001) and
BV (74.5  8.5 vs. 84.8  12.7 mLkg1, P = 0.012) were
diminished in HFpEF patients. Similar results were observed
for BVs expressed in absolute units (PV: 3692  534 vs.
3567  628 mL, P = 0.528; RBCV: 2444  507 vs.
2813  520 mL, P = 0.043) (Fig. 1). Consistent with RBCV
results, Hbmass was reduced in HFpEF patients in relative
Table 1. Baseline demographic and clinical characteristics.
Control HFpEF P
n 15 20
Age (years) 70.6  5.3 71.5  7.3 0.683
Sex (female/male) 2/13 5/15 0.672
Height (cm) 175.4  7.6 169.6  8.9 0.068
Weight (kg) 75.7  11.5 83.8  17.8 0.133
BMI (kgm2) 24.7  3.2 29.2  4.4 0.003
BSA (m2) 1.91  0.17 1.95  0.23 0.609
HR (bpm) 57.9  9.8 62.9  10.3 0.245
SBP (mm Hg) 136.1  14.4 140.4  19.6 0.476
DBP (mm Hg) 80.0  9.0 78.6  9.1 0.653
NT-proBNP (ngL1) 78.1  42.9 823.6  725.6 <0.001
Fasting glucose (mmolL1) 5.5  0.4 5.9  1.1 0.458
eGFR (mLmin1) 82.7  9.5 64.0  20.1 0.002
Hb (gdL1) 14.4  0.6 12.9  1.7 0.002
Ferritin (µgL1) 194.9  110.6 150.9  99.9 0.226
Smoking (yes/no) 0/15 3/20 0.244
Comorbidities (%)
CAD – 55
HTN – 80
DM – 25
Medication (%)
ACEI/ARB – 60
BB – 70
Loop DIU – 60
Lipid lowering – 55
Data are presented as mean  SD, ratio or %.
P < 0.05 (in bold).
ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers; BB, beta-blockers; BMI, body mass index; BSA, body
surface area; CAD, coronary artery disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate;
Hb, hemoglobin; HR, resting heart rate; HTN, hypertension; Loop DIU, loop diuretics; NT-proBNP, N-terminal pro-b-type natriuretic peptide;
SBP, systolic blood pressure.
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(9.6  1.5 vs. 12.2  1.8 gkg1, P < 0.001) and absolute
units (796.2  166.2 vs. 917.6  169.5 g, P = 0.042).
Blood volume-regulating hormones
Figure 2 shows BV-regulating hormones in HFpEF
patients and control individuals. Plasma proANP
(273.2  39.3 vs. 132.5  10.3 pmolL1, P < 0.001),
copeptin (18.3  3.8 vs. 9.2  3.2 pmolL1, P = 0.008),
and aldosterone (104.4  11.4 vs. 64.5  7.1 ngdL1,
P = 0.011) concentrations were substantially augmented
in HFpEF patients. Moreover, HFpEF patients presented
more than twofold enhancement of EPO concentration
(16.0  3.2 vs. 7.3  0.5 UL1, P < 0.001), which
resulted in similar O/P EPO ratio (1.06  0.52 vs.
1.11  0.26, P = 0.227) between groups. Albumin levels
did not differ between HFpEF patients and control indi-
viduals (40.2  3.9 vs. 41.6  1.9 gL1, P = 0.202).
Discussion
The present study assessed intravascular volumes, Hbmass,
and endocrine regulation in stable HFpEF patients and
healthy age- and sex-matched control individuals. The
main findings evidence that HFpEF patients may present
with: (1) preserved PV, (2) marked reductions in RBCV
and Hbmass, resulting in hypovolemia, and (3) augmented
levels of BV-regulating hormones including copeptin,
aldosterone, and EPO, denoting the activation of negative
feedback mechanisms elicited by hypovolemia.
Fluid retention represents a primary clinical manifesta-
tion of decompensation in HF patients (Miller and Mul-
lan 2016). Given the continuous interaction between
extracellular fluids, volume expansion concerns both
interstitial and intravascular constituents. Hypervolemia
entails fundamental alterations of circulatory homeostasis
frequently considered as a life-threatening condition that
requires immediate medical attention (Gheorghiade et al.
2013). Once the patient is acutely treated and stabilized,
some degree of BV expansion persists at clinical dis-
charge, particularly in HF patients with reduced ejection
fraction (HFrEF) (Miller and Mullan 2016). In the short
term, pharmacological interventions decreasing BV may
Table 2. Central hemodynamics and arterial stiffness.
Control HFpEF P
Central hemodynamics
IJV aspect ratio 0.54  0.21 0.71  0.18 0.034
Aortic SBP (mm Hg) 131.0  15.4 134.5  17.7 0.546
Aortic DBP (mm Hg) 80.9  6.1 82.4  10.1 0.620
Aortic Aix@75 (%) 23.7  7.2 25.8  8.9 0.464
Arterial stiffness
Carotid Ddia (mm) 7.37  0.83 7.39  1.15 0.963
Carotid Dsys (mm) 7.77  0.89 7.72  1.13 0.890
Carotid distensibility (103 kPa1) 2.1  1.2 1.6  0.7 0.182
Carotid–femoral PWV (msec1) 8.6  2.1 10.4  2.9 0.047
Data are presented as mean  SD.
P < 0.05 (in bold).
Aix@75, augmentation index adjusted by heart rate of 75 bpm; DBP, diastolic blood pressure; Ddia, diastolic diameter; Dsys, systolic diameter;
PWV, pulse wave velocity; SBP, systolic blood pressure.
HFpEF
Control
∗
A
HFpEF
Control
∗
B
Figure 1. Blood volumes in relative (A) and absolute (B) units in
HFpEF patients and control individuals. Data in bars are presented
as mean  SD. *Significantly different (P < 0.05) between HFpEF
patients and control individuals. BV, blood volume; HFpEF, heart
failure with preserved ejection fraction; PV, plasma volume; RBCV,
red blood cell volume.
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improve the functional status of HFrEF patients (Okonko
et al. 2019, #121). With chronic treatment, however,
HFrEF patients may develop hypovolemia (Anand et al.
1989; Feigenbaum et al. 2000; Bonfils et al. 2010). To
date, hypovolemia in HFpEF patients following standard
pharmacotherapy has been solely supported by indirect
evidence (van Kraaij et al. 2000; 2003; Abramov et al.
2008; Noumi et al. 2011; Montero and Flammer 2017).
The current study demonstrates a 14% reduction in BV
in stable HFpEF patients compared with control individu-
als. In absolute terms, BV levels in HFpEF patients were
slightly lower compared with those of stable HFrEF
patients reported in other studies (Abramov et al. 2008,
#61; Miller 2016, #64) As expected, HFpEF patients also
presented with increased stiffness of central elastic arteries
as determined by augmented carotid–femoral PWV, pre-
viously attributed, among other factors, to the exacer-
bated degradation of elastic fibers in the arterial wall
mediated by proteolytic enzymes such as matrix metallo-
proteinase-2 and -9 (Yasmin et al. 2005; Somleva et al.
2013). With regard to compounding effects of hypov-
olemia and arterial stiffness, experimental studies indicate
that decreased BV impairs ventricular filling, stroke vol-
ume, and cardiac output specifically in the HFpEF
phenotype, notably in the presence of exacerbated stiffen-
ing of the cardiovascular system (Nagano et al. 1997).
Loss of central arterial distensibility limits elastic recoil
and contributes to ventricular diastolic dysfunction, limit-
ing the gradient for venous return, further constrained by
hypovolemia (Luers et al. 2017). In addition, lower cen-
tral BV unloads arterial and cardiopulmonary barorecep-
tors (Montero et al. 2016), inducing a compensatory
response that enhances sympathetic nerve activity and
vasomotor tone (Ryan et al. 2012) as well as activates the
RAAS ultimately leading to increased arterial stiffness
(Fig. S1) (Rehman et al. 2002). Collectively considered,
the apparent hemodynamic stability of HFpEF patients
may be sustained by chronic baroreflex-mediated overac-
tivation of endocrine negative feedback loops attempting
to restore euvolemia.
This investigation reveals another intriguing hemato-
logical characteristic of stable HFpEF patients. While the
high prevalence of anemia, determined from Hb concen-
tration cutoff values, is well established in HF populations
(Brucks et al. 2004; Klapholz et al. 2004; Berry et al.
2005), the cause of anemia is commonly attributed to
hemodilution owing to presumed PV expansion (Senni
et al. 2014). In contrast, the present findings indicate that
true (non-hemodilutional) anemia prevails in HFpEF
patients, exhibiting nearly a one-third reduction in
Hbmass. This concurs with previous studies reporting a
higher prevalence of true anemia in HFpEF compared
with HFrEF patients (Abramov et al. 2008, #61; Miller
2016, #64). Of note, Hbmass, rather than Hb concentra-
tion, is a crucial determinant of maximal oxygen con-
sumption (VO2max), a hallmark of exercise tolerance
routinely used to ascertain cardiac transplant eligibility in
patients with advanced HF (Montero et al. 2015; Montero
and Flammer 2017; Lundby et al. 2017). In the absence of
PV expansion, Hbmass can be substantially reduced despite
the Hb concentration falling within normal limits. The
predominant influence of Hbmass on VO2max is explained
by the former being intrinsically associated with both
hematological (blood oxygen-carrying capacity) and
hemodynamic (BV, ventricular preload) variables deter-
mining convective oxygen delivery (Montero et al. 2015;
Lundby et al. 2017). Hence, a key underlying cause of
severe exercise intolerance, which represents a main
chronic symptom of HFpEF (Montero and Lundby,
2017), may have been concealed in this condition.
The question arises as to which mechanisms underlie
hypovolemia and reduced Hbmass in HFpEF patients. BV
is subjected to endocrine regulation via natriuretic pep-
tides, vasopressin, and the RAAS (Gauer and Henry
1963). These hormones primarily control PV, while EPO
governs erythropoiesis and thus RBCV (Lundby and
Olsen, 2011). When central baroreceptors sense a decrease
HFpEF
Control
Figure 2. Blood volume-regulating hormones in HFpEF patients
and control individuals. Data in bars are presented as mean  SD.
*Significantly different (P < 0.05) between HFpEF patients and
control individuals. EPO, erythropoietin; HFpEF, heart failure with
preserved ejection fraction; proANP, pro-atrial natriuretic peptide.
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in the filling state of the cardiovascular system, afferent
signals to the central nervous system prompt the release
of vasopressin from the posterior pituitary and enhance
efferent sympathetic nervous activity to the kidney stimu-
lating the RAAS hormonal cascade (Montero et al. 2016).
Vasopressin and RAAS hormones facilitate PV retention
as well as stimulate EPO production (Zivny et al. 1972;
Engel and Pagel 1995; Freudenthaler et al. 1999). Herein,
HFpEF patients presented with approximately 1.5- to 2.5-
fold elevations of copeptin (a proxy for vasopressin),
aldosterone, and EPO. A similar increment was observed
for proANP, a natriuretic peptide secreted by atrial cells
in response to atrial stretch with opposite renal effects to
those of vasopressin and RAAS hormones (Goetze et al.
2015). Taking into account the attenuated responsiveness
to natriuretic peptides in HF (Hartupee and Mann 2017),
augmented vasopressin and aldosterone may contribute to
maintain normal PV levels in stable HFpEF patients, most
of which are paradoxically treated with loop diuretics to
prevent eventual decompensation (Montero and Flammer
2017; Hallow et al. 2018). Parenthetically, the ineffective-
ness of neurohormonal antagonism targeting the adrener-
gic system and RAAS in HFpEF implies that this
condition might not involve neurohormonal activation as
a fundamental pathophysiologic mechanism (Oghlakian
et al. 2011); such alteration could merely be a compen-
satory response opposing hypovolemia resulting from a
deficit in RBCV. With respect to the cause(s) of impaired
erythropoiesis in HFpEF patients, the unaltered O/P EPO
ratio denotes adequate EPO production, thus suggesting a
resistance to the action of EPO in the bone marrow.
Among potential culprits, obesity-related systemic low-
grade inflammation may directly alter bone marrow activ-
ity (Redfield, 2016). Erythropoiesis is affected by circulat-
ing pro-inflammatory cytokines as tumor necrosis factor-
alpha interleukin-1 and interferon-gamma, which hinder
erythroid proliferation and differentiation (Means, 1995;
Selleri et al. 1996). Considering the lack of effective treat-
ment for HFpEF (Ponikowski et al. 2016), further
research is warranted to determine the role of potential
phenotypic modifications of the hematopoietic bone mar-
row in this population (Anand and Rector 2014). This
could disclose novel biological targets, notably for those
anemic patients in whom EPO treatment is ineffective or
detrimental (Borovka et al. 2013; Swedberg et al. 2013).
Limitations
There are some limitations to this study that require
comment. The recruitment of stable HFpEF patients with
preserved functional capacity precludes the generalization
of findings to patients with advanced disease, albeit the
demographics and clinical characteristics of the HFpEF
group closely matched those of systematic HF reviews
(Montero et al. 2017). Nonetheless, given the relationship
of cardiovascular disease progression with sedentary
behavior (Ford and Caspersen, 2012), which inexorably
leads to hypovolemia, (Convertino 2007) the reduction in
BV and Hbmass might be exacerbated in later stages of the
HFpEF condition. Moreover, the narrow range of diuretic
doses in our cohort limits the possibility to assess the
specific impact of diuretics on PV and hemodynamics
(Montero and Flammer 2017). Further studies are
required to elucidate the role of prevailing HF therapy
including loop diuretics and neurohormonal antagonists
on BV status and Hbmass in HFpEF patients. In addition,
HFpEF patients may present ID, a prevalent comorbidity
associated with severe diastolic dysfunction and decreased
exercise capacity (Bekfani et al. 2019, #133). In this
respect, experimental studies have demonstrated that ID
directly affects human cardiomyocytes, leading to mito-
chondrial dysfunction and decreased ventricular contrac-
tility and relaxation (Hoes et al. 2018, #134). Despite we
excluded HFpEF patients with a history of ID anemia and
ferritin levels were similar between HFpEF patients and
healthy control individuals, the presence of some degree
of ID cannot be discarded in our study. Finally, the non-
invasive methodology used to estimate CVP, based on the
IJV ratio, be regarded as suggestive rather than definitive.
Conclusion
In stable HFpEF patients, intravascular volume status is
characterized by hypovolemia and reduced Hbmass, in par-
allel to a generalized overactivation of hormones regulat-
ing fluid homeostasis and erythropoiesis. These data
provide key pathophysiological evidence distinguishing a
plausibly prevalent phenotype of HFpEF. The implication
of these findings for identifying effective therapies in this
population remains to be substantiated in future studies.
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